{"effect":{"id":"nausea","name":"Nausea","severity":"mild","description":"Feeling sick to your stomach, sometimes with the urge to vomit. The most commonly reported side effect.","clinicalRates":{"low":0.15,"medium":0.28,"high":0.4},"clinicalRatesNote":"A fixed published-literature dose-response reference (dated 2026-04-12), not derived from this corpus. The predictor uses it only as a fallback when the corpus has no eligible clinical rate points for this effect; otherwise the predictor uses the corpus's own weighted rate. The corpus's own pooled clinical estimate is published alongside — corpusClinical here, rateBase.clinical.pooledEstimate on the per-effect endpoint — and is null when the corpus has no eligible clinical rate points for the effect. Full per-source detail: rateBase.clinical via ?q=effect&id=<id>.","modifiers":{"femaleFactor":1.25,"ageFactor65plus":0.9,"giHistoryFactor":1.4,"diabetesFactor":0.85,"firstMonthFactor":2.5},"modifiersNote":"Odds ratios hand-coded at the 2026-04-12 seed with no per-modifier citation recorded — treat each as an expert-coded prior, not a sourced estimate. The FDR-corrected empirical estimator runs daily but no effect yet meets its evidence bar (model config v1, zero empirical modifiers applied). See ?q=help for the full methodology note.","reportingFrequency":{"mentions":46,"distinctReports":185,"sharePct":24.9,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself — news-aggregator results are excluded, see platforms. Not an incidence rate; not comparable to clinicalRates."},"userReportedSeverity":"Most users describe it as 'manageable' — like mild car sickness. Usually worst in week 1-2, then fades.","onsetDays":"1-3 days after starting or dose increase","durationWeeks":"Typically resolves within 2-4 weeks","managementTip":"Eat smaller meals, avoid fatty food, stay hydrated. Take the injection in the evening so you sleep through the worst.","sources":[{"name":"SURMOUNT-5 Trial (NEJM 2025)","type":"clinical","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2416394","weight":0.3},{"name":"Reddit r/loseit & r/Mounjaro user reports (2024-2026)","type":"user_report","weight":0.4},{"name":"RAND Corporation side effects study (2025)","type":"news","url":"https://www.rand.org/pubs/research_reports/RRA4153-1.html","weight":0.3}]},"dataPointCount":258,"rateBase":{"note":"Only externally citable, non-duplicated rates support an estimate. Shares of spontaneous adverse-event reports (FAERS) are reported separately — they are not incidence.","clinical":{"statedRates":32,"distinctSources":20,"pooledEstimate":{"ratePct":32.3,"ciLowPct":7,"ciHighPct":74,"statedRates":32,"distinctSources":20,"confidence":"high"},"sources":[{"name":"SURMOUNT-5 Trial (NEJM 2025)","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2416394","rate":0.277,"sampleSize":500},{"name":"Nature — Genetic predictors of GLP1 receptor agonist weight loss and side effects (2026)","url":"https://www.nature.com/articles/s41586-026-10330-z","rate":0.35,"sampleSize":27885},{"name":"ClinicalTrials.gov results — A Study of Once-Daily Oral Orforglipron (LY3502970) in Japan — Nausea","url":"https://clinicaltrials.gov/study/NCT05931380#adverse-events","rate":0.333,"sampleSize":60},{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Chinese Participants With Obesity or — Nausea","url":"https://clinicaltrials.gov/study/NCT06023095#adverse-events","rate":0.8,"sampleSize":10},{"name":"ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea","url":"https://clinicaltrials.gov/study/NCT06440980#adverse-events","rate":0.207,"sampleSize":213},{"name":"ClinicalTrials.gov results — A Drug-Drug Interaction (DDI) Study of Orforglipron With Car — Nausea","url":"https://clinicaltrials.gov/study/NCT06370728#adverse-events","rate":0.071,"sampleSize":28},{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Nausea","url":"https://clinicaltrials.gov/study/NCT05086445#adverse-events","rate":0.6,"sampleSize":14},{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Nausea","url":"https://clinicaltrials.gov/study/NCT03929744#adverse-events","rate":0.5,"sampleSize":8},{"name":"ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Nausea","url":"https://clinicaltrials.gov/study/NCT05841238#adverse-events","rate":0.251,"sampleSize":41},{"name":"ClinicalTrials.gov results — A Long-term Safety Study of Orforglipron (LY3502970) in Part — Nausea","url":"https://clinicaltrials.gov/study/NCT06010004#adverse-events","rate":0.235,"sampleSize":135},{"name":"ClinicalTrials.gov results — A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period  — Nausea","url":"https://clinicaltrials.gov/study/NCT05936138#adverse-events","rate":0.167,"sampleSize":6},{"name":"PubMed — Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting ","url":"https://pubmed.ncbi.nlm.nih.gov/37062422/","rate":0.208,"sampleSize":24},{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Compared With Dulaglutide — Nausea","url":"https://clinicaltrials.gov/study/NCT04255433#adverse-events","rate":0.237,"sampleSize":6647},{"name":"ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Nausea","url":"https://clinicaltrials.gov/study/NCT05132088#adverse-events","rate":0.254,"sampleSize":134},{"name":"ClinicalTrials.gov results — A Research Study Comparing RYBELSUS® to Other Blood Sugar Lo — Nausea","url":"https://clinicaltrials.gov/study/NCT05035082#adverse-events","rate":0.048,"sampleSize":500},{"name":"ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Nausea","url":"https://clinicaltrials.gov/study/NCT05548647#adverse-events","rate":0.736,"sampleSize":72},{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Nausea","url":"https://clinicaltrials.gov/study/NCT05564039#adverse-events","rate":0.221,"sampleSize":143},{"name":"ClinicalTrials.gov results — Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidn — nausea","url":"https://clinicaltrials.gov/study/NCT05254418#adverse-events","rate":0.143,"sampleSize":7},{"name":"ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide  — Nausea","url":"https://clinicaltrials.gov/study/NCT04596631#adverse-events","rate":0.258,"sampleSize":66},{"name":"ClinicalTrials.gov results — A Research Study Looking at the Effect of Semaglutide on the — Nausea","url":"https://clinicaltrials.gov/study/NCT05891496#adverse-events","rate":0.341,"sampleSize":22}],"excluded":{"spontaneous_report_share":7,"no_rate":40},"usesPublishedFallback":false},"community":{"statedRates":3,"distinctSources":1,"excluded":{"self_referential":3,"synthetic_source":1,"no_rate":171,"aggregator_result":1},"usesPublishedFallback":false},"spontaneousReportShares":[{"source":"FDA FAERS — semaglutide — NAUSEA","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"semaglutide\"","shareOfReports":0.14,"reports":11506},{"source":"FDA FAERS — tirzepatide — NAUSEA","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"tirzepatide\"","shareOfReports":0.099,"reports":12028},{"source":"FDA FAERS — liraglutide — NAUSEA","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"liraglutide\"","shareOfReports":0.165,"reports":7118},{"source":"FDA FAERS — orforglipron — NAUSEA","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"orforglipron\"","shareOfReports":0.5,"reports":1},{"source":"FDA FAERS — dulaglutide — NAUSEA","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"dulaglutide\"","shareOfReports":0.098,"reports":9986},{"source":"FDA FAERS — exenatide — NAUSEA","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"exenatide\"","shareOfReports":0.127,"reports":12040},{"source":"FDA FAERS — lixisenatide — NAUSEA","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"lixisenatide\"","shareOfReports":0.042,"reports":142}]},"dataPointsBySource":{"clinical":72,"regulatory":7,"user_report":113,"news":66},"sampleDataPoints":[{"sourceName":"SURMOUNT-5 Trial (NEJM 2025)","sourceType":"clinical","sourceUrl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2416394","extractedRate":0.15,"extractedSeverity":"mild","extractedSampleSize":200,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"},{"sourceName":"SURMOUNT-5 Trial (NEJM 2025)","sourceType":"clinical","sourceUrl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2416394","extractedRate":0.28,"extractedSeverity":"mild","extractedSampleSize":500,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"},{"sourceName":"SURMOUNT-5 Trial (NEJM 2025)","sourceType":"clinical","sourceUrl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2416394","extractedRate":0.4,"extractedSeverity":"mild","extractedSampleSize":300,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"},{"sourceName":"Reddit r/loseit & r/Mounjaro user reports (2024-2026)","sourceType":"user_report","sourceUrl":"https://magistra.health/nl/science#nausea","extractedRate":0.15,"extractedSeverity":"mild","extractedSampleSize":200,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"},{"sourceName":"Reddit r/loseit & r/Mounjaro user reports (2024-2026)","sourceType":"user_report","sourceUrl":"https://magistra.health/nl/science#nausea","extractedRate":0.28,"extractedSeverity":"mild","extractedSampleSize":500,"extractionConfidence":"high","scrapedAt":"2026-04-06T11:45:17.713Z"}],"lastUpdated":"2026-08-27"}